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MaOBJECTIVES The purpose of this study was to describe the multimodal outcome 12 months after implantation of
coronary bioresorbable scaffolds (BVS) for the treatment of patients with acute coronary syndromes (ACS).
BACKGROUND Functional and imaging data on the use of BVS are limited to simple, stable lesions; in the setting of
ACS, only short-term clinical follow-up data are available, and no information from intracoronary imaging and vaso-
motion tests has been reported.
METHODS A total of 133 patients (age 62  12 years, 74% males, 15% diabetic) underwent BVS (n ¼ 166) implantation
for the treatment of thrombotic lesions in the setting of ACS (43% non–ST-segment elevation myocardial infarction, 38%
ST-segment elevation myocardial infarction, 20% unstable angina). Clinical, angiographic, intracoronary imaging, and
vasomotor endpoints were evaluated at 12 months.
RESULTS During the 374 days (interquartile range: 359 to 411 days) of follow-up, there were 4 deaths; 3 deﬁnite and 1
probable in-BVS thromboses (all in the ﬁrst 6 months). At 12-month angiography (75 patients, 83 BVS), in-segment late
lumen loss was 0.19  0.45 mm, and 3 (4%) patients showed binary restenosis. Optical coherence tomography (80 BVS,
n ¼ 70) showed a mean lumen area of 6.3  2.3 mm2. Malapposition was evidenced in 21 (26%) BVS. Endothelium-
dependent and -independent vasodilation were observed in 48% and 49% of the BVS.
CONCLUSIONS Twelve months after BVS implantation, clinical, intracoronary imaging, and vasomotion data appear to
provide a rationale for the use of BVS in the setting of ACS and the basis for a randomized study. (J Am Coll Cardiol Intv
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
BVS = bioresorbable scaffolds
MLD = minimum lumen
diameter
OCT = optical coherence
tomography
QCA = quantitative coronary
angiography
STEMI = ST-segment elevation
myocardial infarction
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771of vasomotion, late luminal gain (in contrast to late
luminal loss), and expansive remodeling have been
advocated as potential advantages of BVS over tradi-
tional metal stents (1). These phenomena strongly
rely on modiﬁcations in plaque/vessel biology, but
to date they have been tested only in stable, type
A lesions (2,3). Unstable plaques differ regarding
many basic aspects (e.g., inﬂammation, endothelial
dysfunction/damage, histopathological characteris-
tics) from stable ones, and the previously-mentioned
processes require conﬁrmation in this setting. To
date, only short-term clinical outcomes after BVS im-
plantation are available for patients with acute coro-
nary syndrome (ACS). Although these data appear to
be comparable to second-generation drug-eluting
stents (4–9), important information is still missing,
including longer-term outcome data, as well as an-
giographic, functional, and imaging outcomes.
METHODS
Absorb everolimus-eluting BVS (Abbott Vascular,
Abbott Park, Illinois) are balloon-expandable scaf-
folds consisting of a polymer backbone of poly-
L-lactic acid coated with an amorphous matrix of
poly-D and -L-lactic acid polymer.
ETHICAL CONSIDERATIONS. Since May 2012, BVS
have been commercially available in the European
Union for the treatment of de novo coronary lesions
independently of the patient’s clinical presentation.
The present report includes all consecutive patients
who received a BVS for the treatment of culprit
plaques in the setting of unstable angina with high
thrombotic burden, non–ST-segment elevation myo-
cardial infarction (STEMI) or STEMI between May
2012 and May 2013. Clinical data were collected in an
anonymized way with the approval of the local ethics
committee. Patients who underwent an invasive
follow-up gave written informed consent for the
collection of data within the framework of the pro-
spective MICAT Registry (Ethical committee refer-
ence number 837.123.13 8808-F, NCT02180178).
BVS IMPLANTATION. Implantation was performed
without speciﬁc inclusion/exclusion criteria but
respecting the CE certiﬁcation and manufacturer’s in-
dications. BVS were not used to treat lesions in
the left main coronary, in-stent restenoses, lesions
in bypass, and bifurcation lesions in which a 2-stent
strategy was chosen. No patients were on chro-
nic therapy with anticoagulant agents. Pre-dilation
was performed in all cases; thrombus aspiration and
post-dilation were left to the operator’s discretion.
Aspirin (loading dose 250 to 500mg) was administeredperiprocedurally to patients not on chronic
antiplatelet treatment and was protracted
indeﬁnitely. Dual antiplatelet therapy with
prasugrel, ticagrelor, or clopidogrel was star-
ted periprocedurally with an oral loading dose
and prescribed for 12 months after the event.
FOLLOW-UP. The 12-month clinical follow-
up data were collected from all patients dur-
ing clinical visits or per telephone using
standardized questionnaires. A composite of
cardiovascular death, any myocardial infarc-
tion, and target lesion revascularization
(TLR) was taken as the deﬁnition of a major
adverse event (10). For data quality purposes, all
outcome data were acquired by 1 investigator and
adjudicated by another investigator.
INVASIVE FOLLOW-UP. An invasive 12-month
follow-up was recommended to the ﬁrst 100 pa-
tients given the novelty and complexity of the pro-
cedure. These patients also underwent the following
measurements:
Quant i tat ive coronary ang iography ana lys i s .
Quantitative coronary angiography (QCA) analysis
was performed using Xcelera (Philips, Eindhoven, the
Netherlands). Deﬁnitions are described in Online
Table 1.
Assessment of endothe l ium-dependent and
- independent funct ion . QCA analysis was per-
formed in the scaffolded segment in random order by
staff not aware of the temporal sequence of the im-
ages. Endothelium-dependent and -independent
vasomotion were studied as described in the Online
Appendix and as previously published (11).
Opt ica l coherence tomography . Methods and
deﬁnitions are described in the Online Appendix.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD; categorical variables as
counts and percentages. Responses to vasomotor
stimuli are described as group average and as cumu-
lative frequencies of individual changes in response
to each dose. The changes in minimum lumen diam-
eter (MLD) among time periods (before implantation,
after implantation, and at follow-up) were compared
with 1-way repeated measures analysis of variance.
All analyses were exploratory. All statistical tests
were performed with SPSS version 22 (IBM, Armonk,
New York).RESULTS
Between May 2012 and May 2013, 260 BVS were
implanted in 210 patients for all indications. In the
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TABLE 2 Clinical Outcome of 133 Patients
1–6 Months 6–12 Months
Composite 12 (9.0%) 6 (4.5%)
Cardiac death 4 (3%)* 0 (0%)
STEMI 4 (3%)† 0 (0%)
NSTEMI 2 (1.5%)‡ 3 (2.3%)§
TLR 6 (4.5%)k 3 (2.3%)¶
TVR 7 (5.3%) 7 (5.3%)
Deﬁnite BVS thrombosis 3 (2.3%) 0 (0%)
Probable BVS thrombosis 1 (0.8%) 0 (0%)
Values are n (%). *One death due to lung embolism; 1 sudden death at 18 days of
follow-up (probable in-BVS thrombosis); and the remaining 2 as a consequence of
the index infarction. There was no noncardiac death. †One in nontarget vessel. ‡1
percutaneous coronary intervention in a nontarget vessel, and 1 TLR. §Target
vessel (nontarget lesion) NSTEMI in all 3 cases. kThree in the setting of STEMI for
BVS thrombosis. See Results section. ¶All due to incidental ﬁndings of in-BVS
restenosis at scheduled 12-month angiography, treated with DES. There was no
ARC possible in-BVS thrombosis up to 12 months.
TLR ¼ target lesion revascularization; TVR ¼ clinically-driven target vessel
revascularization (includes TLR); other abbreviations as in Table 1.
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772same period, 133 patients received 164 scaffolds for
the treatment of culprit plaques in the setting of ACS.
CLINICAL CHARACTERISTICS AND OUTCOME.
Follow-up was available in 100% of the patients at
median 374 days (interquartile range: 359 to 411 days)
(Tables 1 and 2). Events have been partially reported
in our previous publication (9). During follow-up, a
total of 18 composite events (13.5%), including 4
deaths (1 sudden death, probable in-BVS thrombosis),
4 STEMIs (all within the ﬁrst 6 months, 3 caused by
in-BVS thromboses treated with DES implantation),
and 5 non-STEMIs (1 due to in-BVS restenosis, also
treated with DES implantation) were observed. There
were another 2 TLRs within the ﬁrst 6 months. In 1
case, the patient presented with unstable angina
3 weeks after the index PCI due to a de novo lesion
>5 mm distal to the BVS. Optical coherence tomog-
raphy (OCT) showed incomplete expansion of the
BVS, which was post-dilated with a good result.
Balloon-only post-dilation of a BVS was performed in
another patient in the setting of a staged procedure
2 weeks after BVS implantation for OCT evidence of
malapposition. The result was controlled with OCT to
exclude recoil in both cases. OCT and post-dilationPatient and Lesion Characteristics
aracteristics (n ¼ 133)
98 (74%)
62  12
nsion 91 (68%)
idemia 40 (30%)
s 20 (15%)
76 (57%)
s MI 14 (11%)
s revascularization 23 (18%)
presentation
NSTEMI, STEMI)
26 (19.6%), 57 (42.9%), 50 (37.6%)
ponin, ng/ml 27.8  51.0
IIa inhibitors 45 (34%)
uration, months 12
pe (ticagrelor,
ugrel, clopidogrel)
44 (33%), 60 (45%), 29 (22%)
l characteristics (n ¼ 166)
reated (LAD, RCX, RCA) 72 (43%), 35 (21%), 59 (36%)
tion 100%
meter, mm 3.0  0.4
gth, mm 19.2  4.6
ation pressure, atm 13.9  2.2
ation 19 (11%)
(%) or mean  SD.
resorbable scaffold; DAPT ¼ dual antiplatelet therapy; GP ¼ glycoprotein; LAD ¼ left
cending; MI ¼myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
RCA ¼ right coronary artery; RCX ¼ circumﬂex; STEMI ¼ ST-segment elevation
infarction; UA ¼ unstable angina.had not been performed at the time of BVS implan-
tation in either case. A third patient showed w50%
BVS restenosis, which was left untreated in the
absence of symptoms and evidence of ischemia
6 months after implantation. Three other patients
showed binary restenoses in the absence of signs of
ischemia at the scheduled 12-month follow-up; all
were treated with PTCA and implantation of a DES.
Representative images of the events are presented in
Figure 1.
QUANTITATIVE CORONARY ANGIOGRAPHY. Control
angiography was performed in 75 patients (83 BVS) at
372 days (interquartile range: 359 to 398 days).
Follow-up was not carried out in 25 of the initially
planned 100 patients who preferred, due to the
absence of symptoms, to undergo exercise tests only
(negative in all cases). Baseline and follow-up angio-
graphic parameters are shown in Table 3 and Online
Table 2. The changes in MLD between index proce-
dure and follow-up and the distribution of late lumen
loss are also shown in Figure 2. In-segment late lumen
loss was 0.19  0.45 mm (range 0.72 to 1.74 mm).
The 3 binary restenoses (3.6% of the BVS, 4% of the
patients) were all observed in-scaffold.
OPTICAL COHERENCE TOMOGRAPHY. OCT was per-
formed in 70 patients (80 scaffolds); data are shown
in Table 4. A total of 14,498 struts were identiﬁed.
The mean length of the scaffold was 19.6  4.8 mm.
A maximum scaffold eccentricity >1.5 was present in
17 (21%) BVS; the maximum value observed was 1.9.
At least 1 malapposed strut was present in 21 (26%)
scaffolds; the mean malapposition area in these
TABLE 3 Quantitative Coronary Analysis Data (In-Segment Analysis, Paired Data)
Pre-Procedure After BVS Implantation Follow-Up p Value
Stenosis length, mm 11  7
MLD, mm 0.6  0.6 2.7  0.6 2.6  0.7 <0.0001*
RVD, mm 3.0  0.8 3.1  0.6 3.1  0.7 >0.5
Acute gain, mm — 2.1  0.8 —
Relative gain — 0.7  0.2 —
Late lumen loss, mm — — 0.19  0.45
Relative loss — — 0.06  0.17
Net gain, mm — — 2.0  0.8
Net gain index — — 0.62  0.24
Loss index — — 0.09  0.26
Binary restenosis (n, % of
patients, % of BVS)
— —
In-scaffold 3 (4%, 3.6%)
Edge 3 (4%, 3.6%)
The p value is for the analysis of variance among the 3 periods. *p > 0.5 for the comparison between immediate
result and follow-up.
BVS ¼ bioresorbable scaffold; MLD ¼ minimal lumen diameter; RVD ¼ reference vessel diameter.
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773patients was 4.1  3.7 mm2. At least 1 uncovered strut
was present in 24 (30%) scaffolds. At follow-up, the
remnant of the culprit plaque could be identiﬁed in 70
cases. The minimum thickness of its cap was 260 
137 mm (range 0 to 620 mm) (Figure 2C).
ENDOTHELIUM-DEPENDENT AND -INDEPENDENT
RESPONSES. Acetylcholine and nitroglycerin re-
sponses were studied in 52 (65%) and 63 (79%) scaf-
folds, corresponding to 49 (70%) and 60 (86%)
patients. All 3 doses of acetylcholine were adminis-
tered in 38 (73%) cases (only the highest dose was not
applied in the right coronary artery and, in case of
vasospasm, at 1 of the lower doses). When analyzed as
the average of all subjects, no signiﬁcant change in
the mean lumen diameter were observed in response
to the infusions (baseline: 2.6  0.51 mm; during sa-
line infusion: 2.5  0.45 mm; acetylcholine dose 1:
2.5  0.45 mm; acetylcholine 2: 2.5  0.43 mm;
acetylcholine 3: 2.3  0.63 mm; nitroglycerin: 2.6 
0.44 mm, p ¼ 0.32). The individual responses to each
dose of acetylcholine and nitroglycerin were, how-
ever, heterogeneous and are presented in Figure 3.
A total of 31%, 33%, and 33% of the in-BVS segments
responded with a dilation to the low-, mid-, and high-
acetylcholine dose, respectively; 21%, 22%, and 37%
responded with a constriction to the low-, mid-, andFIGURE 1 Representative Angiography and OCT Images
ST-segment elevation myocardial infarction before percutaneous corona
month optical coherence tomography (OCT) outcome (A4), showing a 250
(BVS) thrombosis, likely caused by incomplete BVS expansion (MLA 4 mm
D2) malapposition with evidence of peristent staining.high-acetylcholine dose, respectively. Forty-eight
percent of the segments responded with a vasodila-
tion during administration of at least 1 dose of
acetylcholine. Forty-nine percent responded with
vasodilation after nitroglycerin. The mean response
to nitroglycerin was 4  7% (p < 0.001). There were no
complications during follow-up examinations.ry intervention (A1), after percutaneous coronary intervention (A2), and at 12 months (A3); 12-
mm-thick layer of high-intensity, low-attenuation tissue. (B1 and B2) In-bioresorbable scaffold
2) (the scaffold is marked by the white arrow in B1); (C1 and C2) in-BVS restenosis; and (D1 and
FIGURE 2 Late Lumen Loss, MLD, and Cap Thickness
A B C
(A) Distribution of angiographic late lumen loss. The variable was normally distributed (Kolmogorov-Smirnov) with a coefﬁcient of skewness of 0.76 (p ¼ 0.007) and a
coefﬁcient of Kurtosis of 1.59 (p ¼ 0.03). The median was 0.20 mm. (B) Minimum lumen diameter (MLD) before percutaneous coronary intervention (PCI), after PCI, and
at 12 months. (C) Distribution of the minimum thickness of the cap covering the remnants of the culprit lesion.
FIGURE 3 Individu
The % of scaffolded
vasoconstriction (ora
choline; GTN ¼ nitro
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774DISCUSSION
BVS are currently approved for use independently of
the lesion and clinical presentation. Data in patientsal Responses to Acetylcholine and Nitroglycerin
segments that responded with vasodilation (green), responded with
nge), or responses <2 SD of the mean error (blue). Ach ¼ acetyl-
glycerin.with ACS remain, however, limited to clinical out-
comes and to the periprocedural period or short-term
(1-month) follow-up (4,5,8,9). We report on the
12-month clinical, angiographic, intracoronary imag-
ing, and functional outcomes of a single-center
cohort of unselected, consecutive patients treated
with BVS in the setting of ACS.
SUMMARY OF THE DATA. Clinical outcome. The com-
posite endpoint rate of 13.5% was expectedly higher
than those previously observed in stable patients (10),
but comparable with those of previous randomized
controlled studies or all-comer registries enrolling
ACS patients treated with DES (12–16) (incidence
variable between 4.9% and 26.3% on the basis of
deﬁnitions used, clinical presentation, and extent of
disease). The large majority of events occurred in the
ﬁrst 6 months. The incidence of restenosis was quite
low and was comparable to that of DES (12–16). The
incidence of deﬁnite in-BVS thrombosis, in line with
our recently reported ﬁgures from a larger dataset of
patients (17), was relatively high and will require
further attention.
Angiographic outcome. Late lumen loss was very
modest and comparable to previous BVS papers in
stable settings (3,10). For comparison, the value
observed in the SPIRIT trial with second-generation
drug-eluting stents was 0.23  0.29 mm at 12
months, that is, slightly larger than that observed
here (18). A total of 3 (4%) BVS showed binary reste-
nosis at the 12-month follow-up, and were asymp-
tomatic in all cases. Taken together, these data
support the use of BVS with respect to the prevention
TABLE 4 Optical Coherence Tomography Data
General (80 BVS)
Scaffold length, mm 19.6  4.8
Analyzed struts, n per scaffold 186  55
Lumen (80 BVS)
Mean area, mm2 6.3  2.3 (1.9–15)
Minimum area, mm2 4.2  1.8 (0.4–8.7)
Maximum area, mm2 8.9  4.5 (2.9–31.9)
Maximum eccentricity 1.5  0.2 (1.2–1.9)
Scaffold (80 BVS)
Minimum area, mm2 5.6  1.9 (1.2–10.3)
Maximum area, mm2 8.2  1.9 (2.5–17.1)
Maximum eccentricity 1.4  0.2 (1.1–1.9)
Neointima (80 BVS)
Maximum thickness, mm 358  170 (110–1,070)
Maximum % area stenosis 28  14 (8–74)
Maximum burden, mm2 1.95  0.78 (0.59–5.05)
Malapposed struts
Malapposition detected,
n (% of scaffolds with at
least 1 malapposed struts),
n of struts (% of struts)
21 (26%), 156 (1.1%)
Malapposed struts, n per scaffold 12.4  15 (1–58)*
Malapposed struts per patient, % 7.1  8.1 (0.5–26.3)*
Incomplete strut apposition area, mm2 4.1  3.7 (0.5–11.1)*
Malapposition length, mm 1.9  1.6 (1–8)*
BVS with at least 1% malapposed struts 18 (22.5%)
>5% malapposed struts 9 (11.25%)
Uncovered struts
Uncovered struts detected, n
Patients 24 (32%)
Struts 121 (0.8%)
Uncovered struts per patient 5.0  5.0 (1–20)
Uncovered struts per patient, % 3.1  3.2 (0.7–14)*
BVS with at least 1% uncovered 18 (22.5%)
At least 5% uncovered 4 (5%)
Values are mean  SD, mean  SD (range), or n (%). Data are presented per
scaffold unless otherwise noted. *Only patients with malapposition (n ¼ 21
patients, n ¼ 21 scaffolds) or uncovered struts (n ¼ 24) were entered for this
analysis.
BVS ¼ bioresorbable scaffold.
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775of acute occlusion and recoil at implantation and the
inhibition of neointima proliferation in the subse-
quent period.
Int racoronary imaging . Neointima thickness, area,
and % restenosis in our cohort were comparable to
that observed in metal stents in similar settings (19).
The incidence of malapposition was also very similar
to that observed after DES implantation in the setting
of STEMI (20). The malapposition area was, however,
larger as compared with that reported immediately
after BVS implantation (21). The rate of uncovered
struts was low and was comparable to previous data
in metal stent and BVS (19).
Finally, the remnants of the culprit plaque were
covered in the majority of cases (95.7%) by ahomogeneous, signal-rich tissue that was thicker than
65 mm (the threshold commonly used for discrimi-
nating thin- from thick-cap ﬁbroatheroma in de novo
lesions [22]). Findings of a layer presenting OCT
characteristics possibly compatible with those of a
ﬁbrous cap have been previously hypothesized to
witness the transformation of vulnerable lesions to
stable plaques (1). This hypothesis (and the existence
of a threshold for a “stable” cap) remains speculative
and will need prospective validation.
Endothel ia l funct ion . Acetylcholine responses are
an accepted diagnostic and risk stratiﬁcation tool (23),
but data on the functional restoration of lesions
responsible for an acute event have not been reported
before. In our population, endothelium-dependent
and -independent vasodilation were observed in
about one-half of the lesions, a ﬁgure that might
improve after further withdrawal of the scaffolding
function of the BVS (and the effects of everolimus).
Evidence of vasoconstriction in 37% of the lesions at
the highest acetylcholine dose, however, points to
the long-term persistence of vascular spasm phe-
nomena in a subgroup of patients.
STUDY LIMITATIONS AND STRENGTHS. The fact that
this was not a randomized, controlled trial does not
allow us to exclude the existence of an inclusion bias
even though patients were consecutively enrolled
without inclusion/exclusion criteria. To guarantee
data quality, all data were entered by 1 researcher and
were monitored against original clinical documents
by another one. Control coronary angiography was
not performed in some of the patients in the absence
of symptoms or other evidence of ischemia. This
obviously represents a negative bias against the de-
vice; since the outcomes reported are in line with
those of other studies in stable settings, however,
we do not believe that this bias played a signiﬁcant
role. No control group was included in this report;
however, we previously showed that the clinical
characteristics and short-term outcome of these pa-
tients, consecutively included in the present report,
do not differ from those of patients who received
metal stents during the same period in our institution
(9), and the vast majority of the clinical events
occurred early after implantation. As well, the vaso-
motion properties of BVS are obviously unique, and a
control group would have added no information with
regard to this endpoint. Because OCT was not sys-
tematically performed at implantation, we cannot
conclude whether this was present directly after im-
plantation of whether it was acquired at later time-
points (e.g., as the effect of the dissolution of thrombi
jailed between scaffold struts and vessel wall).
PERSPECTIVES
WHAT IS KNOWN? Outcome data on the use of BVS
are to date limited to simple, stable lesions; these
studies report a normalization of vascular function as
early as 1 year after scaffold implantation. The phys-
iology and pathology of thrombotic lesions is however
radically different, and these data cannot be directly
extrapolated to the setting of acute coronary syn-
dromes. In this setting, only short-term clinical
follow-up data are available, and no information from
intracoronary imaging and vasomotion tests has been
reported.
WHAT IS NEW? We report clinical, intracoronary
imaging and vasomotion data 12 months after BVS
implantation in patients with thrombotic lesions: our
data support the concept of vascular and lesion
regeneration after scaffold implantation.
WHAT IS NEXT? Further data, with a longer
follow-up, are now necessary.
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776Whatever the mechanism, the implications of the
resulting ﬂow disturbances will have to be further
investigated. Despite the high resolution of OCT, the
identiﬁcation of uncovered struts is challenging and
to a certain extent arbitrary, and the incidence of
uncovered struts, in this like in other reports, should
be interpreted cautiously. The maximum percent
restenosis measured by OCT was larger than theo-
retically expected on the basis of late lumen loss
measures. Differences in the resolution of the
methods, the nonuniform distribution of neointima,
and the fact that scaffold struts are invisible at x-ray
might concur to explain this discrepancy.
CONCLUSIONS
Long-term outcome data after BVS implantation are
limited to chronic stable settings, type A lesions, and
patients selected using stringent inclusion/exclusion
criteria (24). In the current report, we provide the ﬁrst
clinical, functional, and imaging outcome data at 12
months in an unselected cohort of high-risk patients
who received 1 or more BVS for the treatment of a
thrombotic culprit lesion. Collectively, the incidence
of events was high but comparable to that of previous
series with metal stents; the implications of malap-
posed struts and the episodes of in-BVS thrombosis
will require further assessments. Finally, the evi-
dence that the majority of the lesions was covered by
a high-intensity, low-attenuation layer suggestive of
ﬁbrotic neointima as well as the normalization of
endothelial responses in about 50% of the lesions
provide a biological background for the use of BVS in
the treatment of culprit lesions and provide the
rationale for a large-scale, long-term follow-up trial.ACKNOWLEDGMENTS The authors wish to thank
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